Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLUL | P15104 | 1/20 | 0.70 |
| ▸ | GRM8 | O00222 | 1/20 | 0.62 |
| ▸ | GRM6 | O15303 | 1/20 | 0.62 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.62 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.62 |
| ▸ | BHMT | Q93088 | 1/20 | 0.59 |
| ▸ | GCLC | P48506 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31230376 | 1.00 | GLUL (0.70) | GLULGRM8GRM6GRM7GRM4 | |
| SCHEMBL1969235 | 1.00 | GLUL (0.70) | GLULGRM8GRM6GRM7GRM4 | |
| SCHEMBL12648443 | 1.00 | GLUL (0.70) | GLULGRM8GRM6GRM7GRM4 | |
| Hydrochloric Acid SCHEMBL8842420 | 0.98 | GLUL (0.68) | GLULGRM8GRM6GRM7GRM4 | |
| Water SCHEMBL21747433 | 0.98 | GLUL (0.68) | GLULGRM8GRM6GRM7GRM4 | |
| Water SCHEMBL21747423 | 0.98 | GLUL (0.68) | GLULGRM8GRM6GRM7GRM4 | |
| Water SCHEMBL21747432 | 0.98 | GLUL (0.68) | GLULGRM8GRM6GRM7GRM4 | |
| Methyl Alcohol SCHEMBL28474438 | 0.96 | GLUL (0.66) | GLULGRM8GRM6GRM7GRM4 | |
| D-Glutamate SCHEMBL6861834 | 0.90 | GRM8 (0.69) | GLULGRM8GRM6GRM7GRM4 | |
| Glutamic Acid SCHEMBL6861840 | 0.90 | GRM8 (0.69) | GLULGRM8GRM6GRM7GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1427 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103494-A1 | GENE THERAPY TREATMENT | UNIVERSITY OF SHEFFIELD (GB) | 2026-04-16 | — | — | US | claimed |
| US-20260083744-A1 | METHODS TO STRENGTHEN VISUAL PATHWAYS | GEORGIA TECH RES INST (US) | 2026-03-26 | — | — | US | claimed |
| EP-4712970-A2 | COMPOUNDS FOR TREATING HEREDITARY SPASTIC PARAPLEGIA | The Children's Medical Center Corporation (US) | 2026-03-25 | — | — | EP | claimed |
| EP-4694882-A2 | COMPOUNDS FOR TREATING RETT SYNDROME AND OTHER DISORDERS | Unravel Biosciences, Inc. (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4601463-A1 | GENE THERAPY TREATMENT | University of Sheffield (GB) | 2025-08-20 | — | — | EP | claimed |
| CN-120035379-A | Gene therapy treatment | 谢菲尔德大学 | 2025-05-23 | — | — | CN | claimed |
| WO-2024243015-A2 | COMPOUNDS FOR TREATING HEREDITARY SPASTIC PARAPLEGIA | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-11-28 | — | — | WO | claimed |
| WO-2024215967-A2 | COMPOUNDS FOR TREATING RETT SYNDROME AND OTHER DISORDERS | UNRAVEL BIOSCIENCES, INC. (US) | 2024-10-17 | — | — | WO | claimed |
| CN-118684620-A | Betel nut alkaloid and preparation method and application thereof | 暨南大学 | 2024-09-24 | — | — | CN | claimed |
| US-20240200050-A1 | AMINOACYL TRANSFER RNA SYNTHETASES | TRUSTEES OF TUFTS COLLEGE (US) | 2024-06-20 | — | — | US | claimed |
| EP-0904777-A1 | Use of an excitatory amino acids inhibitor in cosmetic or dermatological compositions for sensitive kin and composition obtained | L'OREAL (FR) | 1999-03-31 | — | — | EP | claimed |
| US-5873812-A | REDUCING PROSTHETIC ORGAN AND TISSUE REJECTION; BINDING EXCESS ALDEHYDE FIXATIVE BY TREATMENT WITH AN AMINOCARBOXYLIC ACID IN ACIDIC MEDIUM | SORIN BIOMEDICA CARDIO S.P.A. (IT) | 1999-02-23 | — | — | US | claimed |
| EP-0845217-A1 | Inhibiting undesirable taste in oral compositions | THE PROCTER & GAMBLE COMPANY (US) | 1998-06-03 | — | — | EP | claimed |
| EP-0795337-A2 | A method of preparing biological implantation material | SORIN BIOMEDICA CARDIO S.p.A. (IT) | 1997-09-17 | — | — | EP | claimed |
| US-5500420-A | Metabotropic glutamate receptor agonists in the treatment of cerebral ischemia | CORNELL RESEARCH FOUNDATION, INC. (US) | 1996-03-19 | — | — | US | claimed |
| WO-1995028081-A1 | ADDRESSING BAIT AVERSION BY DISRUPTING ASSOCIATIVE LEARNING | THE MEAT INDUSTRY RESEARCH INSTITUTE OF NEW ZEALAND INC. (NZ) | 1995-10-26 | — | — | WO | claimed |
| US-5202257-A | Pure DNA which is capable of hybridizing with receptor polynucleotides under mild conditions | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1993-04-13 | — | — | US | claimed |
| EP-0497884-A1 | GLUTAMATE RECEPTOR COMPOSITIONS AND METHODS | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1992-08-12 | — | — | EP | claimed |
| WO-1991006648-A1 | GLUTAMATE RECEPTOR COMPOSITIONS AND METHODS | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1991-05-16 | — | — | WO | claimed |
| EP-0127429-B1 | PROCESS FOR PREPARING OPTICALLY ACTIVE ((3-AMINO-3-CARBOXY)PROPYL-1) PHOSPHINIC ACID DERIVATIVES | MEIJI SEIKA KAISHA LTD. (JP) | 1989-04-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083744-A1 | METHODS TO STRENGTHEN VISUAL PATHWAYS | GRM6, GRM3, GRM2 | GLUL 544/4885GRM8 15/4885GRM6 1/4885 |
| US-20260103494-A1 | GENE THERAPY TREATMENT | AP3B1, PAIP1, AP2B1 | GLUL 3458/4885GRM8 2956/4885GRM6 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.